Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse Effect Levels and in Risk-Based Prioritization. - Paul Friedman K; Gagne M; Loo LH; Karamertzanis P; Netzeva T; Sobanski T; Franzosa JA; Richard AM; Lougee RR; Gissi A; Lee JJ; Angrish M; et al. (Toxicological sciences : an official journal of the Society of Toxicology, 2020)